Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol → 2-(1-((2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | 2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol | HCID 59603426 | — |
| 반응물 | 2-(azetidin-1-yl)-1H-benzo[d]imidazole | HCID 59605883 | — |
| 생성물 | 2-(1-((2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol | HCID 59605223 | — |
반응 단계
2-(1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol (75 mg) was reacted with 2-(azetidin-1-yl)-1H-benzo[d]imidazole (33 mg) via General Procedure I for Buchwald coupling to give 35.9 mg 455 following reverse phase purification. MS (Q1) 546.3 (M)+
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08173650B2 |
| 출처 데이터셋 | uspto-grants-2012_05 |
| ORD ID | ord-19650ecf64d04be48e321c798db8ee51 |
| 출처 메모 | uspto-grants-2012_05 |